124 related articles for article (PubMed ID: 11098728)
1. [Pharmacologic treatment for cognitive disorders: an update].
Lestage P
Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
[TBL] [Abstract][Full Text] [Related]
2. Citicoline: pharmacological and clinical review, 2006 update.
Secades JJ; Lorenzo JL
Methods Find Exp Clin Pharmacol; 2006 Sep; 28 Suppl B():1-56. PubMed ID: 17171187
[TBL] [Abstract][Full Text] [Related]
3. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
Parnetti L; Mignini F; Tomassoni D; Traini E; Amenta F
J Neurol Sci; 2007 Jun; 257(1-2):264-9. PubMed ID: 17331541
[TBL] [Abstract][Full Text] [Related]
4. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
5. Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.
Kamkwalala AR; Newhouse PA
Curr Alzheimer Res; 2017; 14(4):377-392. PubMed ID: 27697062
[TBL] [Abstract][Full Text] [Related]
6. AMPA receptor potentiators as cognitive enhancers.
O'Neill MJ; Dix S
IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Alzheimer's disease].
López OL; Becker JT
Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
[TBL] [Abstract][Full Text] [Related]
8. Emerging cognitive enhancing drugs.
Buccafusco JJ
Expert Opin Emerg Drugs; 2009 Dec; 14(4):577-89. PubMed ID: 19772371
[TBL] [Abstract][Full Text] [Related]
9. [Nootropes (cognition enhancers) and neuroprotectors].
Vornin TA; Seredenin SB
Eksp Klin Farmakol; 2007; 70(4):44-58. PubMed ID: 18078043
[TBL] [Abstract][Full Text] [Related]
10. [A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Arushanian EB
Eksp Klin Farmakol; 2010 Mar; 73(3):35-9. PubMed ID: 20408429
[TBL] [Abstract][Full Text] [Related]
11. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats.
Antonini V; Prezzavento O; Coradazzi M; Marrazzo A; Ronsisvalle S; Arena E; Leanza G
J Neurochem; 2009 May; 109(3):744-54. PubMed ID: 19245662
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological attenuation of electroconvulsive therapy--induced cognitive deficits: theoretical background and clinical findings.
Pigot M; Andrade C; Loo C
J ECT; 2008 Mar; 24(1):57-67. PubMed ID: 18379337
[TBL] [Abstract][Full Text] [Related]
13. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11.
Park CH; Choi SH; Koo JW; Seo JH; Kim HS; Jeong SJ; Suh YH
J Neurosci Res; 2002 Nov; 70(3):484-92. PubMed ID: 12391609
[TBL] [Abstract][Full Text] [Related]
14. Neuropharmacology of cognition and memory: a unifying theory of neuromodulator imbalance in psychiatry and amnesia.
Vakalopoulos C
Med Hypotheses; 2006; 66(2):394-431. PubMed ID: 16300905
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
17. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences.
Kuhad A; Chopra K
Eur J Pharmacol; 2007 Dec; 576(1-3):34-42. PubMed ID: 17822693
[TBL] [Abstract][Full Text] [Related]
18. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia.
Caston JC; Diehl LA; Hedgepath AW
J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232
[No Abstract] [Full Text] [Related]
19. Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?
Lockhart BP; Lestage PJ
Exp Gerontol; 2003; 38(1-2):119-28. PubMed ID: 12543269
[TBL] [Abstract][Full Text] [Related]
20. [The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion].
Horváth S
Orv Hetil; 2001 Feb; 142(8):383-9. PubMed ID: 11263076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
